Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 17/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394078 | 0.93 | TLR8 (0.62) | TLR8TLR7L3MBTL1NUDT1 | |
| SCHEMBL29507644 | 0.93 | TLR8 (0.62) | TLR8TLR7L3MBTL1NUDT1 | |
| SCHEMBL13613798 | 0.92 | TLR7 (0.58) | TLR8TLR7 | |
| SCHEMBL5400928 | 0.90 | TLR7 (0.46) | TLR8TLR7L3MBTL1PPARG | |
| SCHEMBL5750439 | 0.86 | TLR8 (0.56) | TLR8TLR7NUDT1 | |
| SCHEMBL5057099 | 0.85 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL30345323 | 0.85 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL14500921 | 0.84 | EPHX2 (0.40) | — | |
| SCHEMBL5348699 | 0.84 | TLR7 (0.57) | TLR7 | |
| SCHEMBL5362385 | 0.84 | TLR7 (0.64) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | claimed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | claimed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214675-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7078523-B2 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050215581-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-29 | — | — | US | disclosed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | disclosed |
| US-6660735-B2 | Inducing cytokine biosynthesis; viral diseases, neoplastic disorders | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR8 273/4885TLR7 84/4885L3MBTL1 3263/4885 |
| US-20050215581-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR8 273/4885TLR7 84/4885L3MBTL1 3263/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR8 273/4885TLR7 84/4885L3MBTL1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.